TCGA-CV-7421-01A-11R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.000457
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.490
- ANGIOGENESIS+0.450
- HYPOXIA+0.320
- WNT_BETA_CATENIN_SIGNALING+0.310
- UV_RESPONSE_DN+0.300
- COAGULATION+0.290
- APICAL_JUNCTION+0.250
- GLYCOLYSIS+0.240
- HEDGEHOG_SIGNALING+0.220
- ADIPOGENESIS+0.200
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.480
- G2M_CHECKPOINT-0.380
- INTERFERON_GAMMA_RESPONSE-0.380
- ALLOGRAFT_REJECTION-0.330
- E2F_TARGETS-0.310
- IL6_JAK_STAT3_SIGNALING-0.260
- MITOTIC_SPINDLE-0.230
- INFLAMMATORY_RESPONSE-0.220
- PI3K_AKT_MTOR_SIGNALING-0.200
- MYC_TARGETS_V2-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518172 | — | E | 0.830 |
| 2 | TCGA-CV-7177-01A-11R-2016-07 | — | — | 0.826 |
| 3 | e2ac493b-9157-4756-8949-edf4b7f334cd | — | — | 0.816 |
| 4 | SRR8613707 | — | C | 0.787 |
| 5 | TCGA-A8-A06P-01A-11R-A00Z-07 | — | A | 0.778 |
| 6 | SRR8613710 | — | F | 0.778 |
| 7 | MBCProject_0504_T1_RNA | — | A | 0.772 |
| 8 | X9d79253b.8c45.4bde.a42d.c399fb107400 | — | cohortMD2 | 0.770 |
| 9 | 4df6c488-ef2f-4019-a1b0-3a3624039be8 | — | — | 0.766 |
| 10 | 20060030.TNBC | — | F | 0.765 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.490 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| HYPOXIA | 0.320 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.150 | Inavolisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.110 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.070 | Remibrutinib | — uncovered |